SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biopharma Update on the Novel Coronavirus: May 11
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
May 11, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
BioForest
Clinical Catch-Up: May 4-8
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
May 8, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: May 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
May 8, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
May 7, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
May 6, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
May 5, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
May 4, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biotech Professionals Express Fears…and Hope, During Pandemic
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
May 1, 2020
 · 
5 min read
 · 
Gail Dutton
Bio NC
Clinical Catch-Up: April 27-May 1
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
May 1, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
PassPort Technologies, Inc. Initiated US Phase I Clinical Trial of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine
February 23, 2024
 · 
2 min read
Drug Development
Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years
February 23, 2024
 · 
3 min read
Drug Development
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
February 23, 2024
 · 
5 min read
Drug Development
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
February 22, 2024
 · 
5 min read
Drug Development
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024
 · 
4 min read
Drug Development
Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications
February 22, 2024
 · 
3 min read
Drug Development
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
February 22, 2024
 · 
6 min read
Drug Development
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
February 22, 2024
 · 
6 min read
Drug Development
LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V
February 22, 2024
 · 
4 min read
Drug Development
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
 · 
5 min read
Drug Development
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis
February 21, 2024
 · 
4 min read
Drug Development
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
February 21, 2024
 · 
6 min read
Drug Development
Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer
February 21, 2024
 · 
7 min read
Drug Development
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies
February 21, 2024
 · 
5 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
February 20, 2024
 · 
6 min read
Drug Development
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
February 20, 2024
 · 
8 min read
Drug Development
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
February 20, 2024
 · 
2 min read
Drug Development
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
February 20, 2024
 · 
4 min read
Drug Development
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
 · 
5 min read
Drug Development
Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments
February 20, 2024
 · 
4 min read
Load More